NAMS NewAmsterdam Pharma Co N.V.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1936258 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-26.4%
TTM net income YoY7.3%
TTM EPS YoY17.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-900.1%
Net margin-789.9%
FCF margin-581.6%
EBITDA margin-899.0%
Returns
ROE-30.2%
ROA-27.8%
ROIC (approx.)-92.8%
Asset turnover0.04x
Leverage & solvency
Liabilities / assets8.3%
Debt / equity0.00x
Current ratio11.76x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.73x
Accruals ratio-7.4%
Payout ratio—
Capex / revenue1.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $19.16M | $3.70M | $3.04M | $32,000 | $348,000 | $19.14M | $2.98M | $12.77M |
| R&D expense | $39.36M | $41.67M | $38.01M | $38.59M | $30.97M | $27.52M | $44.75M | $34.90M |
| SG&A expense | $24.00M | $26.89M | $23.45M | $27.42M | $24.52M | $27.26M | $27.15M | $21.11M |
| Operating income | -$44.19M | -$64.86M | -$58.42M | -$65.98M | -$55.14M | -$35.63M | -$68.92M | -$43.23M |
| Pretax income | -$16.18M | -$64.14M | -$48.44M | -$74.92M | -$72.00M | -$17.36M | -$39.53M | -$92.18M |
| Income tax | $1.21M | — | — | — | — | — | — | $0 |
| Net income | -$17.39M | -$64.14M | -$48.44M | -$74.92M | -$72.00M | -$17.36M | -$39.53M | -$92.18M |
| EBITDA | -$44.12M | -$64.78M | -$58.36M | -$65.92M | -$55.02M | -$35.53M | -$68.87M | -$43.18M |
| EPS (basic) | -0.14 | -0.52 | -0.40 | — | -0.61 | -0.15 | -0.34 | — |
| EPS (diluted) | -0.14 | -0.52 | -0.40 | — | -0.61 | -0.15 | -0.34 | — |
| Weighted avg. shares (diluted) | 124.14M | 123.37M | 121.72M | — | 119.00M | 118.56M | 116.12M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $423.13M | $424.15M | $457.61M | $490.00M | $538.41M | $563.86M | $748.42M | $771.74M |
| Short-term investments | $205.11M | $209.70M | $178.50M | $146.24M | $164.54M | $175.30M | $60.06M | $62.45M |
| Current assets | $672.16M | $659.21M | $658.04M | $675.70M | $732.33M | $769.85M | $817.30M | $863.41M |
| PP&E, net | $554,000 | $411,000 | $379,000 | $383,000 | $323,000 | $312,000 | $238,000 | $242,000 |
| Total assets | $687.99M | $704.45M | $732.64M | $769.28M | $786.43M | $815.11M | $818.41M | $864.62M |
| Current liabilities | $57.15M | $72.97M | $67.42M | $85.79M | $58.27M | $36.51M | $40.91M | $106.92M |
| Total liabilities | $57.20M | $73.03M | $67.42M | $85.85M | $58.36M | $36.62M | $41.05M | $107.12M |
| Shareholders' equity | $630.78M | $631.42M | $665.22M | $683.43M | $728.07M | $778.50M | $777.36M | $757.50M |
| Shares outstanding | 119.82M | 117.65M | 116.64M | 114.40M | 113.17M | 112.51M | 112.17M | 108.06M |
| Cash flow statement | ||||||||
| Operating cash flow | -$39.77M | -$39.21M | -$30.60M | -$40.88M | -$32.77M | -$37.67M | -$36.47M | -$37.48M |
| Capital expenditure | $177,000 | $80,000 | $38,000 | $100,000 | $42,000 | $88,000 | $16,000 | $3,000 |
| Free cash flow | -$39.95M | -$39.29M | -$30.64M | -$40.98M | -$32.81M | -$37.76M | -$36.48M | -$37.48M |
| Investing cash flow | $33.70M | -$4.76M | -$11.51M | -$21.14M | $2.51M | -$159.14M | $2.85M | -$62.18M |
| Financing cash flow | $5.45M | $11.04M | $11.06M | $13.68M | $5.89M | $3.42M | $6.52M | $456.61M |
| Depreciation & amortization | $67,000 | $89,000 | $62,000 | $59,000 | $125,000 | $107,000 | $52,000 | $51,000 |
| Stock-based compensation | $12.52M | $18.38M | $18.00M | $14.02M | $15.01M | $15.18M | $15.21M | $9.41M |
Free plan shows the latest 8 periods; Pro shows all 15 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.